Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis

Nutrition and Cancer

Volumn 62, Issue 3, 2010, Pages 371-378

  Baldwin, Cindy ^a   Millette, Mathieu ^a,b   Oth, Daniel ^a   Ruiz, Marcia T ^a   Luquet, François Marie ^a   Lacroix, Monique ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b Bio K+ International Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FAS LIGAND; FLUOROURACIL; PROBIOTIC AGENT; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL TUMOR; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLUOROURACIL; HUMANS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; PROBIOTICS;

LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI;

EID: 77951134075     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903407197     Document Type: Article

References (41)

1. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics, 2008. Toronto, Ontario, Canada.
2. Jemal A, Siegel S, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2008. CA Cancer J Clin 58, 71-96, 2008.
3. Fornarini G, Guglielmi A, and Sobrero A: The handling of metastatic colorectal cancer. Ann Oncol 16, ii141-ii143, 2005.
4. Machover DA: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80, 1179-1187, 1997.
5. Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134, 1296-1310, 2008.
6. Capurso G, Marignani M, and Delle Fave G: Probiotics and the incidence of colorectal cancer: when evidence is not evident. Digest Liv Dis 38, S277-S282, 2006.
7. Scheinbach S: Probiotics: functionality and commercial status. Biotechnol Adv 16, 581-608, 1998.
8. Adolfsson O, Meydani SN, and Russell RM: Yogurt and gut function. Am J Clin Nutr 80, 245-256, 2004.
9. Perdigon G, Locascio M, MediciM, Pesce deRuizHolgado A, andOliverG: Interaction of bifidobacteria with the gut and their influence in the immune function. Biocell 27, 1-9, 2003.
10. Food and Agriculture Organization-World Health Organization: Probiotics in food health and nutritional properties and guidelines for evaluation (FAO/WHO working group report). Food and Agriculture Organization of the United Nations-World Health Organization, Rome, Italy, 2006.
11. Roller M, Pietro Femia A, Caderni G, Rechkemmer G, et al.: Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br J Nutr 92, 931-938, 2004. (Pubitemid 40028854)
12. GoldinBRandGorbach SL:Clinical indications for probiotics: an overview. Clin Inf Dis 46, S96-S100, 2008.
13. HirayamaKand Rafter J: The role of probiotic bacteria in cancer prevention. Microbes Inf 2, 681-686, 2000.
14. Rafter J: Lactic acid bacteria: mechanistic perspective. Br J Nutr 88, S89-S94, 2002.
15. Beausoleil M, Fortier N, Gúenette S, L'Ecuyer A, Savoie M, et al.: Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 21, 732-736, 2007.
16. Millette M, Luquet FM, and Lacroix M: In vitro growth control of selected pathogens by Lactobacillus acidophilus- andLactobacillus casei-fermented milk. Lett Appl Microbiol 44, 314-319, 2007.
17. Millette M, Luquet FM, Ruiz MT, and Lacroix M: Characterization of probiotics properties of Lactobacillus strains. Dairy Sci Technol 88, 695-705, 2008.
18. Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1, 1458-1461, 2006.
19. Takahashi H, Yoneda K, Tomimoto A, Endo H, Fujisawa T, et al.: Lifestylerelated diseases of the digestive system: colorectal cancer as a life stylerelated disease: from carcinogenesis to medical treatment. J Pharmacol Sci 105, 129-132, 2007.
20. Marshall JR: Prevention of colorectal cancer: diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am 37, 73-82, 2008.
21. Macdonald JS: Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 54, S4-S11, 2004.
22. Foligne B, Nutten S, Grangette C, Dennin V, Gouderdcourt D, et al.: Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 13, 236-243, 2007.
23. Maldonado Galdeano C and Perdiǵon G: The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 13, 219-226, 2006.
24. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, et al.: 5-fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 78, 986-992, 1998.
25. Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, et al.: Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 83, 1380-1386, 2000.
26. Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, et al.: Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis 16, 245-252, 1995.
27. Biffi A, Coradini D, Larsen R, Riva L, and Di Fronzo G: Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line. Nutr Cancer 28, 93-99, 1997.
28. Ganjam LS, Thornton WH Jr, Marshall RT, and Macdonald RS: Antiproliferative effects of yogurt fractions obtained by membrane dialysis on cultured mammalian intestinal cells. J Dairy Sci 80, 2325-2329, 1997.
29. Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, et al.: Lactobacillus- and Bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer 26, 365-380, 1996
30. Blatt NB and Glick GD: Signaling pathways and effector mechanisms pre-programmed cell death. Bioorg Med Chem 9, 1371-1384, 2001.
31. Micheau O, Solary E, Hammann A, Martin F, and Dimanche- Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89, 783-789, 1997.
32. Ciccolini J, Peillard L, Evrard A, Cuq P, Aubert C, et al.: Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clin Cancer Res 6, 1529-1535, 2000.
33. Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leit̃ao C, et al.: Inhibition of Fas expression by RNAi modulates 5- fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta 1772, 40-47, 2007.
34. Nagane M, HuangHJ, and Cavenee WK: The potential of TRAIL for cancer chemotherapy. Apoptosis 6, 191-197, 2001.
35. Haupt S, Berger M, Goldberg Z, andHauptY: Apoptosis-the p53 network. J Cell Sci 116, 4077-4085, 2003.
36. Javelaud J and Besançon F: [P21WAF1/CIP1: un inhibiteur de l'apoptose]. Med Sci 16, 265-266, 2000.
37. Mahyar-RoemerMand Roemer K: p21Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20, 3387-3398, 2001.
38. Xu SQ and El-DeiryWS: p21 (WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269, 179-190, 2000.
39. Park E, Jeon GI, Park JS, and Paik HD: A probiotic strain of Bacillus polyfermenticus reduces DMH induced precancerous lesions in F344 male rat. Biol Pharm Bull 30, 569-574, 2007.
40. Ö sterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, et al.: Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97, 1028-1034, 2007.
41. Kim Y, Lee D, Kim D, Cho J, Yang J, et al.: Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch Pharm Res 31, 468-473, 2008.